Innoviva reported a strong 2025, driven by significant growth in its specialty therapeutics segment and stable royalty cash flows. The company achieved substantial revenue and net income growth, bolstered by favorable investment valuations and strategic product approvals, positioning it for continued expansion in 2026.
Total revenue grew 25% year-over-year to $114.6 million in Q4 2025 and 15% year-over-year to $411.3 million for the full year 2025.
positiveNet product sales more than doubled year-over-year to $59.1 million in Q4 2025 and increased 77% year-over-year to $172.1 million for the full year 2025.
positiveFDA approval of NUZOLVENCE® for gonorrhea in December 2025 addresses a critical public health need.
positiveInitiated a $125 million share repurchase program in the fourth quarter.
positiveRoyalty revenue decreased 11.6% year-over-year to $58.4 million in Q4 2025 and 1.9% year-over-year to $250.3 million for the full year 2025.
attentionIncome from operations decreased to $39.0 million in Q4 2025 from $43.1 million in Q4 2024, and decreased to $163.7 million for the full year 2025 from $166.9 million for the full year 2024, reflecting increased R&D investments.
attentionInventory levels increased to $39.2 million in FY2025 from $33.7 million in FY2024.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Royalty revenue, net | N/A | — | — | — |
Net product sales | N/A | — | — | — |
License and other revenue | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
2025 marked an excellent year for Innoviva, demonstrating strength across all areas of our business, with 15% revenue growth to over $400 million and net income exceeding $270 million.
Our royalty business continued to provide stable and resilient cash flow, while IST generated 47% year-over-year U.S. sales growth to $119 million.
We expanded our commercial portfolio with the successful mid-2025 launch of ZEVTERA in the U.S., received nominations for two of our products for the prestigious 2025 Prix Galien USA Award, and ended the year on an exciting note with the FDA approval of our fifth product, NUZOLVENCE.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.